Clinical trial
A Study of V950 in People With Alzheimer Disease (V950-001 AM7)
NCT00464334 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00464334 |
|---|---|
| Title | A Study of V950 in People With Alzheimer Disease (V950-001 AM7) |
| Official title | A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Biological |
| Interventions | V950, ISCOMATRIX™, Placebo to V950 |
| Enrollment | 86 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Apr 23, 2007 |
| Last update posted | Sep 25, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: